Estrategias de tratamiento antibiótico para la neumonía adquirida en la comunidad en adultos
Antibiotic treatment strategies for communityacquired pneumonia in adults
Contenido principal del artículo
Descargas
Detalles del artículo
Referencias (VER)
Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O,et al. β-Lactam monotherapy vs. β-lactam-macrolide combination treatment in moderately severe community-acquired
pneumonia: a randomized noninferiority trial. JAMA Int Med. 2014;174(12).
Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340-6.
File TM Jr, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am. 2013;27(1):99-104-14.
Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-Lactam monotherapy for the treatment of community- adquired pneumoniae in adults: a systematic review and metaanalysis. J Antimicrob Chemother. 2014;69(6):1441-6.
Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community-adquired pneumonie in hospitalized
adults. Cochrane Datebase Syst Rev. 2012;12:9.
Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005; 40(9):1288-97.
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-90.